Search Results
Your search for ,HIS matches 4425 pages
Showing 1951 - 2000When Can Patients With Gleason 6 Prostate Cancer Safely Undergo Active Surveillance?
Prior to ASCO’s 2016 endorsement of the Cancer Care Ontario (CCO) guideline on active surveillance in the management of localized prostate cancer,1 most men—over 90%—diagnosed with low-risk localized disease were treated with active therapy.2 Today, about 50% of American men with low-risk disease...
Eric Tetzlaff, MHS, PA-C, DFAAPA, Receives 2018 AAPA Publishing Award
ERIC TETZLAFF, MHS, PA-C, DFAAPA, a physician assistant at Fox Chase Cancer Center, has received the American Academy of Physician Assistants (AAPA) 2018 Publishing Award for his article, “National Study of Burnout and Career Satisfaction Among Physician Assistants in Oncology: Implications for...
In Cases Where Early Detection of Metastatic Disease Offers No Advantage, Why Conduct Routine Surveillance?
“What is a reasonable plan of follow-up for patients with cancers for which early detection of metastatic disease offers no advantage?” Posing that question during his Presidential Address at the 2018 Society of Surgical Oncology (SSO) Annual Cancer Symposium, Kelly M. McMasters, MD,PhD,...
Study Finds Gender Disparities in Head and Neck Cancer Treatment and Outcomes
An analysis of cancer registry data from a California hospital system showed that women with head and neck cancer were less likely to receive intensive chemotherapy (35% vs 46%) and radiation (60% vs 70%) compared to men. Controlling for factors such as age and serious medical conditions, a...
Expert Point of View: Colin D. Weekes, MD, PhD and Manish A. Shah, MD, FASCO
Two pancreatic cancer specialists commented on the PREOPANC-1 study for The ASCO Post: Colin D. Weekes, MD, PhD, of Massachusetts General Hospital and Harvard Medical School, Boston, who had discussed the abstract at the ASCO Annual Meeting, and Manish A. Shah, MD, FASCO, Chief of the Solid Tumor...
A. Oliver Sartor, MD, on Issues in Immunotherapy
A. Oliver Sartor, MD, of Tulane University, speaks anecdotally about immunotherapy for prostate cancer and shares his experiences in speaking to patients with late-stage disease about the knowns, unknowns, risks, and toxicities of using a therapy outside the context of a clinical trial setting. The ...
Owen A. O’Connor, MD, PhD, on Issues in Immunotherapy
Owen A. O'Connor, MD, PhD, of Columbia University Medical Center, shares his perspective on immunotherapy for patients with late-stage cancer in the context of a clinical trial setting and recent Right-to-Try legislation. The content in this post has not been reviewed by the American Society of...
Andrew D. Seidman, MD, on Embracing Computer-Assisted Decision-Making
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, discusses the benefits of decision support tools, especially for the oncologist who treats a variety of cancers in his or her practice. The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. ...
New Fellows Begin 2018–2019 ASCO Health Policy Fellowship Program
TREVOR ROYCE, MS, MD, MPH, and Sheetal Kircher, MD, are the 2018–2019 ASCO Health Policy Fellows. Now entering its third year, the fellowship program offers oncologists the opportunity to gain the knowledge, skills, and experience necessary to shape regulatory and legislative policies that directly ...
Excerpt From the 2018 ASCO Presidential Address: ‘Delivering Discoveries: Expanding the Reach of Precision Medicine’
In my area of research, lung cancer, precision medicine is indeed transforming the treatment of this disease and has important implications for other cancers and for the future of our patients with cancer. Today’s achievement of being able to systematically identify genomic changes that can be...
A Humble Beginning Built on Commitment: The Life and Times of Lee S. Schwartzberg, MD, FACP
In this edition of the Living a Full Life series, guest editor Jame Abraham, MD, interviewed medical oncologist Lee S. Schwartzberg, MD, FACP, Executive Director at the West Cancer Center, Memphis. Dr. Schwartzberg’s major research interests are new therapeutic approaches to breast cancer,...
Mariusz A. Wasik, MD, Joins Fox Chase as Chair of Pathology
MARIUSZ A. WASIK, MD, has been appointed Chair of the Department of Pathology at Fox Chase Cancer Center and Jeanes Hospital. He will also serve as Associate Director of the Cancer Center, a position he assumed on July 2, 2018. As Chair of Pathology and a key member of Fox Chase’s leadership...
Carnegie Corporation Honors Antoni Ribas, MD
THE CARNEGIE CORPORATION of New York named University of California, Los Angeles (UCLA) Professor Antoni Ribas, MD, an honoree as part of its Great Immigrants Initiative, a program honoring a selected group of naturalized citizens who have made notable contributions to the progress of American...
Early Data Suggest TLR9 Agonist May Combat PD-1 Resistance in Advanced Melanoma
COMBINING CMP-001, a Toll-like receptor 9 (TLR9) agonist, plus pembrolizumab (Keytruda) appears to overcome resistance to anti–programmed cell death protein 1 (anti–PD-1) therapy, according to a preliminary phase Ib study.1 Adding CMP-001 to pembrolizumab was well tolerated, with antitumor efficacy ...
Genome Sequencing of Blood Samples May Lead to Detection of Early- Stage Lung Cancer
IF THE INITIAL promise of research presented at the 2018 ASCO Annual Meeting bears fruit, we may one day have a simple blood test to screen for early-stage lung cancer and possibly other cancers. Although it is still very early days for this test, an initial report from the ongoing Circulating...
Expert Point of View: Warren Chow, MD, and Douglas S. Hawkins, MD
WARREN CHOW, MD, a sarcoma specialist at City of Hope, Duarte, California, said maintenance therapy has not traditionally been used in the treatment of rhabdomyosarcoma; therefore, the findings represent “a paradigm shift.” Although the RMS2005 Maintenance study established a new standard of care ...
With European Protocol, Maintenance Therapy Improved 5-Year Survival in Rhabdomyosarcoma
THE ADDITION OF 6 months of maintenance chemotherapy in the treatment of rhabdomyosarcoma improved 5-year survival by 13%, in the European RMS2005 Maintenance study reported at the 2018 ASCO Annual Meeting.1 “At the end of this long, not-easy study, we concluded that maintenance is an effective and ...
With Compassion Toward None, With Technology for All?
Imagine health care in the not too distant future… JOHN IS GOING about his usual Saturday at home, when his health-care–enabled smart watch alerts him to a sudden rise in his heart rate. As he is wondering about the reason, he feels a sharp pain in his left lower quadrant. The tachycardia...
Expert Point of View: Charles Drake, MD, PhD
“THIS TRIAL is a clear winner for the treatment of squamous non–small cell lung cancer [NSCLC],” stated formal discussant Charles Drake, MD, PhD, of Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York. “The concept underlying the combination of checkpoint...
Many Childhood Cancer Survivors Not Concerned About Their Future Health
A research team led by a St. Jude Children’s Research Hospital epidemiologist has conducted the largest analysis to date of how adult survivors of childhood cancer view their health risk. The scientists found that a surprisingly high number of survivors showed a lack of concern for their...
Lessons in the Chill of Early Morning
The following essay by Sushil Bhardwaj, MD, is adapted, with permission, from The Big Casino: America’s Best Cancer Doctors Share Their Most Powerful Stories, which was coedited by Stan Winokur, MD, and Vincent Coppola and published in May 2014. The book is available on Amazon.com and...
A Medical Oncologist Urges Men to Keep Their Prostates
With the development of the prostate-specific antigen (PSA) test in the early 1990s, the urology community advocated for population screening of all men of a certain age, igniting a heated argument about the test’s clinical value vs potential harms that has not abated to this day. Moreover, from...
STAG2 Genetic Test Could Reduce Overtreatment in Some Patients With Bladder Cancer
A new genetic test in bladder cancer could be key to reducing the cost of care while avoiding overtreatment in some patients, according to research published by Waldman et al in Clinical Cancer Research. Deciding whether to treat bladder cancer aggressively can be difficult—predictive...
Expensive Cancer Drugs Don’t Work if Patients Can’t Afford Them
Eight years ago, I was having a series of colds I couldn’t shake and pain that radiated throughout my back. Still, my symptoms weren’t concerning until, on Halloween morning in 2010, I stepped out of bed and fell to the floor in excruciating pain, unable to move. A visit to the emergency room and a ...
Three Cancer Researchers Share Tang Prize in Biopharmaceutical Science
The 2018 Tang prize in Biopharmaceutical Science is being shared by three cancer researchers, including targeted cancer therapy researcher John Mendelsohn, MD, former President of The University of Texas MD Anderson Cancer Center; Tony Hunter, PhD, Professor of Biology at the Salk Institute; and ...
Marc E. Lippman, MD, MACP, FRCP, Returns to Georgetown’s Cancer Center
Georgetown Lombardi Comprehensive Cancer Center announces the return of physician-scientist Marc E. Lippman, MD, MACP, FRCP, as Professor of Oncology and Medicine at the Georgetown University Medical Center. From 1988 to 2001, Dr. Lippman served as Director of Georgetown Lombardi Comprehensive...
Steven T. Rosen, MD, Inducted Into AIMBE College of Fellows
City of Hope Comprehensive Cancer Center’s Provost and Chief Scientific Officer, Steven T. Rosen, MD, has been inducted into the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE). Dr. Rosen was nominated, reviewed, and elected by peers in recognition of...
Raising Awareness of the Financial Impact of Cancer on Young Adult Survivors
GUEST EDITOR Adolescent and Young Adult Oncology explores the unique physical, psychosocial, social, emotional, sexual, and financial challenges adolescents and young adults with cancer face. The column is guest edited by Brandon Hayes-Lattin, MD, FACP, Associate Professor of Medicine and Medical...
Ensuring High-Quality Oncology Care for Patients With Intellectual Disabilities
Despite significant gains in improved access to public places, transportation, and job opportunities for people with disabilities since the enactment of the Americans With Disabilities Act in 1990, the long history of discrimination in the social and medical treatment of people with disabilities is ...
Percutaneous Ablation vs Nephrectomy in T1a Kidney Cancer
Many cases of early-stage kidney cancer can be treated with a relatively new, nonsurgical procedure used to destroy tumors, a new study by Talenfeld et al in Annals of Internal Medicine suggests. The procedure, called percutaneous ablation, involves the insertion of a needle through the skin into...
Dietary Insulin Load and Risk of Disease Recurrence in Stage III Colon Cancer
New research led by Dana-Farber Cancer Institute investigators suggests that patients treated for nonmetastatic colon cancer may sharply reduce the risk that the disease will return by following a diet low in carbohydrates and other foods that raise insulin levels. In a study published by...
Inside Story on the Genesis of Teen Cancer America
THANK YOU for publishing the excellent article “We Need to Fill the Gap Between Pediatric and Adult Oncology Care” by Sarah Stream (as told to Jo Cavallo) in the March 25, 2018, issue of The ASCO Post. Sarah’s story and her connection to Teen Cancer America actually go much deeper than she reported ...
Jens Hillengass, MD, Named Chief of Myeloma at Roswell Park
JENS HILLENGASS, MD, has been announced as the new Chief of Myeloma of the Roswell Park Comprehensive Cancer Center. As part of his new role, Dr. Hillengass will continue his research on hematologic diseases, including multiple myeloma and its precursor diseases. A scientist with more than 15...
From Italy to Boston, A Love of Molecular Diagnostics Shapes a Career for Valentina Nardi, MD
Valentina Nardi, MD, is a staff pathologist at Massachusetts General Hospital, and her current clinical work includes implementing molecular assays for hematologic malignancies at the Center for Integrated Diagnostics. “I was born in Rome, but I did my high school and college education in Genoa. I ...
Steven A. Rosenberg, MD, PhD, Receives American College of Surgeons Jacobson Innovation Award
THE 2018 JACOBSON INNOVATION AWARD of the American College of Surgeons was recently presented to Steven A. Rosenberg, MD, PhD, Chief of the Surgery Branch at the National Cancer Institute (NCI) as well as Professor of Surgery at the Uniformed Services University of Health Sciences and at the...
How Learning What’s on Your Patient’s Bucket List May Improve Care
It may sound too good to be true, but asking patients a simple question about what is on their bucket list can actually spark a dialogue about how best to make their cancer care and survivorship fit into their life plans, as well as be an effective way to identify their end-of-life care goals,...
Voluntarily Stopping Eating and Drinking Is Legal—and Ethical—for Terminally Ill Patients Looking to Hasten Death
Terminally ill patients with cancer will sometimes ask their clinicians for help with assisted or hastened death.1 Although palliative care and hospice care can usually address the concerns of most patients, some have physical or existential suffering that is refractory to comfort and supportive...
Dan Theodorescu, MD, PhD, Appointed Director of Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai
DAN THEODORESCU, MD, PhD, has been named Director of the Samuel Oschin Comprehensive Cancer Institute at Cedars-Sinai, a position he will assume starting July 1, 2018. Dr. Theodorescu, a translational cancer researcher and expert in bladder cancer, will direct the oncology enterprise at...
Prostate Cancer Therapy in Evolution: Time to Rethink and Redirect?
The ASCO updated guidelines on the treatment of metastatic non-castrate prostate cancer penned by Morris and his colleagues1 provide valuable information annotated to the strengths of evidence in recently reported prostate cancer studies. CHAARTED, GETUG-AFU 15, LATITUDE, and STAMPEDE have...
Richard J. Bleicher, MD, FACS, Appointed Vice Chair of SSO’s Breast Fellowship Program Directors Committee
Richard J. Bleicher, MD, FACS, Professor of Surgical Oncology at Fox Chase Cancer Center, has been appointed Vice Chair of the Breast Fellowship Program Directors Committee of the Society of Surgical Oncology (SSO). In his new leadership role within SSO, Dr. Bleicher will be involved in the breast ...
The Raven
The call from the dermatologist came at noon on Good Friday, just after my wife left with our two young daughters for a week on her family’s tree farm in Northern Michigan. I was on call for the hospital inpatient leukemia service, so I could not join them. When the dermatologist solemnly began,...
Minimal Residual Disease Testing in AML: Still a Shifting Target
Testing for minimal residual disease (MRD) has become an established part of the management of acute lymphoblastic leukemia (ALL), but in acute myeloid leukemia (AML), the technology still warrants validation. To address issues and set new standards, the European LeukemiaNet Working Party recently ...
AMA Rejects Recommendation to Reaffirm Opposition to Medical Aid in Dying
On June 11, the American Medical Association (AMA) House of Delegates voted 56% to 44% to reject a report by its Council on Ethical and Judicial Affairs (CEJA) that recommended the AMA maintain its Code of Medical Ethics’ opposition to medical aid in dying. Instead, the House of Delegates...
AUA 2018: Finasteride Reduces Risk of Prostate Cancer and Is Safe, Long-Term Results Show
Twenty-five years after it opened for enrollment, the Prostate Cancer Prevention Trial (PCPT) has delivered a final verdict: finasteride, a common hormone-blocking drug, reduces men's risk of getting prostate cancer without increasing their risk of dying from the disease. Initial study...
Surveillance Intensity Not Associated With Earlier Detection of Recurrence or Improved Survival in Patients With Colorectal Cancer
A national retrospective study led by researchers at The University of Texas MD Anderson Cancer Center found no association between intensity of posttreatment surveillance and detection of recurrence or overall survival (OS) in patients with stage I, II, or III colorectal cancer. Published by...
John V. Cox Reflects on 10 Years as Editor-in-Chief of the Journal of Oncology Practice
John V. Cox, DO, FASCO, of the Parkland Hospital and Health System/University of Texas Southwestern Medical Center, has served as the Editor-in-Chief of the Journal of Oncology Practice (JOP) since 2008. As a member of the journal’s inaugural Editorial Board, he has seen the publication evolve...
ASCO to Present Douglas W. Blayney, MD, FASCO, With Joseph V. Simone Award and Lecture
ASCO will recognize Douglas W. Blayney, MD, FASCO, medical oncologist and Professor at Stanford University School of Medicine, with the Joseph V. Simone Award and Lecture for Excellence in Quality and Safety in the Care of Patients with Cancer. Dr. Blayney will be presented with the award at the...
Study Evaluates Effect of Restrictive Opioid Protocol After Gynecologic Surgery
THE NUMBER of opioids prescribed after surgery for gynecologic cancer decreased significantly after implementation of an ultra-restrictive opioid prescription protocol, with no apparent negative effect on patient satisfaction or pain, according to research presented by Jaron Mark, MD, and...
‘Pearls of Wisdom’ for Leadership and Success in Academic Medicine Gathered Over a 35-Year Career
Dr. Hayes, ASCO President 2016–2017, is Professor of Internal Medicine; Stuart B. Padnos Professor in Breast Cancer; and Clinical Director of the Breast Oncology Program at the University of Michigan Comprehensive Cancer Center, Ann Arbor. AS I COMPLETE my 3-year term as ASCO President, I am...
The X-Ray Era: 1901–1915
The text and photographs on this page are excerpted from a four-volume series of books titled Oncology: Tumors & Treatment, A Photographic History, by Stanley B. Burns, MD, FACS, and Elizabeth A. Burns. The photos below are from the volume titled “The X-Ray Era: 1901–1915.” The photographs...
